John A. Tarello Named Chairman of the Board

PEABODY, MA (April 27, 2004) – John W. Wood, President and CEO of Analogic Corporation (NASDAQ: ALOG), announced today that the Company has received an order for forty of its EXplosive Assessment Computed Tomography (EXACT™) Systems from L-3 Communications (NYSE: LLL) Security Systems Corporation, and has given L-3 an option to purchase fifty additional units. The EXACT is the “heart” of L-3’s eXaminer™ 3DX 6000, a certified Explosive Detection System (EDS), containing L-3 patented technologies, that has been purchased by the U.S. Transportation Security Administration (TSA) and installed at major airports across the U.S. The L-3 systems are also installed at a number of international airports, such as Singapore’s Changi Airport and Italy’s Fiumicino and Ciampino airports. Analogic has delivered over 500 EXACTs to L-3 to date.

These units will be delivered over the next nine months to meet anticipated foreign as well as domestic demand. L-3 recently received an order from the Israel Airport Authority to supply five eXaminer units for the new Ben Gurion Airport terminal, and granted the Authority an option to purchase as many as twenty systems.

Analogic Corporation is a leading designer and manufacturer of advanced health and security systems and subsystems sold to Original Equipment Manufacturers (OEMs). The Company is recognized worldwide for advancing the state of the art in Computed Tomography (CT), Digital Radiography (DR), Ultrasound, Magnetic Resonance Imaging (MRI), Patient Monitoring, Cardiovascular Information Management, and Embedded Multiprocessing.

This press release contains the Company’s or management’s intentions, hopes, beliefs, expectations or predictions. These are considered “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements (statements which are not historical facts) in this presentation are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements, including statements about product development, market and industry trends, strategic initiatives, regulatory approvals, sales, profits, expenses, price trends, research and development expenses and trends, and capital expenditures involve risk and uncertainties and actual events and results may differ significantly from those in any forward-looking statements. Actual results may differ materially from those indicated by such statements as a result of various factors, including those discussed in the Company’s periodic reports filed with the SEC.